Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

OSLO, Norway, March 3, 2026 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA^®), has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA), enabling commercial launch in China.

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure. With Cevira’s regulatory approval in China, Photocure is eligible for a milestone payment with further sales milestones based on future revenue.

The announcement from Asieris states: „As the world’s first non-surgical, non-invasive therapy for patients with cervical intraepithelial neoplasia grade 2 (CIN2), APL-1702 is expected to fill a critical clinical gap in this therapeutic area and redefine a massive, previously underserved market for non-invasive cervical disease treatment.